Clinical Trials
22 trialsInterleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Providence Health & Services
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
Case Comprehensive Cancer Center
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
National Institutes of Health Clinical Center (CC)
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer
National Cancer Institute (NCI)
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
National Cancer Institute (NCI)
Lymphocyte Therapy in Treating Patients With Kidney Cancer
National Cancer Institute (NCI)
Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery
National Cancer Institute (NCI)
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Hoag Memorial Hospital Presbyterian
Biological Therapy in Treating Patients With Metastatic Cancer
Hoag Memorial Hospital Presbyterian